Drug intelligence / Profile preview

cisplatin + etoposide + mitomycin c

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous

Overview

A chemotherapy combination regimen consisting of cisplatin, etoposide, and mitomycin C. This regimen has been studied for the treatment of advanced non-small cell lung cancer (NSCLC). In clinical trials, it demonstrated an objective response rate of 41% with a median duration of response of 21 weeks and median survival of 38 weeks. However, it is associated with significant neurologic toxicity (peripheral neuropathy and ototoxicity) and hematologic toxicity.

Other names: PEM regimen

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on cisplatin + etoposide + mitomycin c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + etoposide + mitomycin c.

Explore the full profile